Malee Warnnissorn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Malee Warnnissorn has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Pattama Chaopotong
Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand
2 shared publications - Boonlert Viriyapak
Department of Obstetrics and Gynecology
1 shared publication Chanon Neungton
Department of Obstetrics and Gynecology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
1 shared publication- Irene Ruengkhachorn
Gynecologic Oncology Division, Department of Obstetrics & Gynecology, Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand
1 shared publication - Nida Jareemit
Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand
1 shared publication - Pornphet Songsirithat
Department of Obstetrics and Gynecology
1 shared publication
Latest Publications
- 24 July 2026
- Published by Wolters Kluwer Health in Journal of Lower Genital Tract Disease
- Vol. 30 (4) , 318-324
Investigating Discrepancies Between Original and Review Diagnoses in Cervical Cancer and Precancerous Lesions
Objective: Pathologic diagnosis is essential for guiding the management of precancerous and cancerous cervical lesions. However, discrepancies between original and review pathology reports may significantly impact treatment decisions. This study aimed to evaluate the prevalence and associated factors of pathologic discrepancies in cervical lesions. Methods: This retrospective observational study included patients referred with a diagnosis of precancerous or cancerous cervical lesions between 2013 and 2023. Eligible cases required availability of both original and review pathology reports. Pathologic data from the original and review reports were retrospectively collected and compared. Discrepancies were categorized as major (those influencing treatment decisions or involving missing/critical information) or minor (those not impacting treatment). Clinical and pathologic variables, including turnaround times for the review process, were also analyzed. Results: A total of 376 cases were included. Specimens comprised biopsy/endocervical curettage (42.3%), conization (46.8%), and hysterectomy (10.9%). The mean patient age was 49.6 ± 12.9 years. Immunohistochemistry was used in 4% of original and 4.3% of review examinations. The median review turnaround time was 3 days (IQR, 1 to 6), extended to 6 days (IQR, 4.3 to 12) when additional immunohistochemistry was required. Overall, 58.2% of cases demonstrated discrepancies: 33.2% major and 25% minor. The 3 most common major discrepancies were changes in pathologic diagnosis, lymphovascular space invasion, and tumor size. Multivariable analysis showed no clinical factors associated with major discrepancies. Conclusion: Pathology review revealed a high rate of discrepancies in cervical lesions, with significant clinical implications. Mandatory review is warranted for preinvasive and invasive cervical lesions.
- 24 July 2026
- Published by Wolters Kluwer Health in Journal of Lower Genital Tract Disease
- Vol. 30 (4) , 318-324
Investigating Discrepancies Between Original and Review Diagnoses in Cervical Cancer and Precancerous Lesions
Objective: Pathologic diagnosis is essential for guiding the management of precancerous and cancerous cervical lesions. However, discrepancies between original and review pathology reports may significantly impact treatment decisions. This study aimed to evaluate the prevalence and associated factors of pathologic discrepancies in cervical lesions. Methods: This retrospective observational study included patients referred with a diagnosis of precancerous or cancerous cervical lesions between 2013 and 2023. Eligible cases required availability of both original and review pathology reports. Pathologic data from the original and review reports were retrospectively collected and compared. Discrepancies were categorized as major (those influencing treatment decisions or involving missing/critical information) or minor (those not impacting treatment). Clinical and pathologic variables, including turnaround times for the review process, were also analyzed. Results: A total of 376 cases were included. Specimens comprised biopsy/endocervical curettage (42.3%), conization (46.8%), and hysterectomy (10.9%). The mean patient age was 49.6 ± 12.9 years. Immunohistochemistry was used in 4% of original and 4.3% of review examinations. The median review turnaround time was 3 days (IQR, 1 to 6), extended to 6 days (IQR, 4.3 to 12) when additional immunohistochemistry was required. Overall, 58.2% of cases demonstrated discrepancies: 33.2% major and 25% minor. The 3 most common major discrepancies were changes in pathologic diagnosis, lymphovascular space invasion, and tumor size. Multivariable analysis showed no clinical factors associated with major discrepancies. Conclusion: Pathology review revealed a high rate of discrepancies in cervical lesions, with significant clinical implications. Mandatory review is warranted for preinvasive and invasive cervical lesions.
- 25 September 2024
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 50 (11) , 2081-2092
Oncological outcomes and risk factors for recurrence of mucinous borderline ovarian tumors: A 15‐year experience at a tertiary center
Background: The most common subtype of borderline ovarian tumors in Asia is mucinous borderline ovarian tumors (mBOTs). Intraoperative distinction from mucinous carcinoma can be difficult. Despite the indolent behavior of mBOTs, recurrence or metastases may occur. The objectives of this study were to determine the oncological outcomes of mBOTs and the risk factors for their recurrence.Results: This retrospective study enrolled patients with mBOTs treated or referred to our institution between January 2005 and December 2019. Histological reviews of the recurrent cases (primary and recurrent or metastatic tumors) were performed. Patients with other tumor subtypes, pseudomyxoma peritonei, or no in‐house operation were excluded. Two hundred thirty‐two patients were diagnosed with mBOTs. The median follow‐up was 52 months. Six patients (2.58%) had tumor recurrence or metastasis. The risk factors for recurrence were a ruptured tumor, residual tumor after an operation, high serum CA19‐9 level, and stage of the disease. The recurrence rates of fertility‐sparing and radical surgery were not significantly different. Detailed surgical staging, intraepithelial carcinoma, and microinvasion were also not associated with disease recurrence.Conclusions: mBOTs have an excellent prognosis. Currently, fertility‐sparing surgery is the standard treatment, showing no significant difference in oncological outcomes compared to radical surgery. Patients with risk factors should be closely monitored.
- 25 September 2024
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 50 (11) , 2081-2092
Oncological outcomes and risk factors for recurrence of mucinous borderline ovarian tumors: A 15‐year experience at a tertiary center
Background: The most common subtype of borderline ovarian tumors in Asia is mucinous borderline ovarian tumors (mBOTs). Intraoperative distinction from mucinous carcinoma can be difficult. Despite the indolent behavior of mBOTs, recurrence or metastases may occur. The objectives of this study were to determine the oncological outcomes of mBOTs and the risk factors for their recurrence.Results: This retrospective study enrolled patients with mBOTs treated or referred to our institution between January 2005 and December 2019. Histological reviews of the recurrent cases (primary and recurrent or metastatic tumors) were performed. Patients with other tumor subtypes, pseudomyxoma peritonei, or no in‐house operation were excluded. Two hundred thirty‐two patients were diagnosed with mBOTs. The median follow‐up was 52 months. Six patients (2.58%) had tumor recurrence or metastasis. The risk factors for recurrence were a ruptured tumor, residual tumor after an operation, high serum CA19‐9 level, and stage of the disease. The recurrence rates of fertility‐sparing and radical surgery were not significantly different. Detailed surgical staging, intraepithelial carcinoma, and microinvasion were also not associated with disease recurrence.Conclusions: mBOTs have an excellent prognosis. Currently, fertility‐sparing surgery is the standard treatment, showing no significant difference in oncological outcomes compared to radical surgery. Patients with risk factors should be closely monitored.
- Open Access
- 12 September 2013
- Published by Wiley in Case Reports in Obstetrics and Gynecology
- Vol. 2013, 1-4
Extramedullary Hematopoiesis in the Uterine Cervix Associated with Tissue Repair
Extramedullary hematopoiesis (EMH) is the presence of hematopoietic precursors outside the bone marrow. This condition is usually associated with hematologic disorders. Although EMH can be found in almost every site in the body, female genital tract involvement is rare. The authors report EMH in the uterine cervix from a 64-year-old patient following cervical biopsy due to abnormal cervical cytology. Neither neoplasm nor hematologic disorder was detected before the diagnosis and after 1 year of follow up. To the best of our knowledge, this is the first reported case of EMH involving the uterine cervix which showed an association with tissue repair.
- 12 September 2013
- Published by Wiley in Case Reports in Obstetrics and Gynecology
- Vol. 2013, 1-4
Open AccessExtramedullary Hematopoiesis in the Uterine Cervix Associated with Tissue Repair
Extramedullary hematopoiesis (EMH) is the presence of hematopoietic precursors outside the bone marrow. This condition is usually associated with hematologic disorders. Although EMH can be found in almost every site in the body, female genital tract involvement is rare. The authors report EMH in the uterine cervix from a 64-year-old patient following cervical biopsy due to abnormal cervical cytology. Neither neoplasm nor hematologic disorder was detected before the diagnosis and after 1 year of follow up. To the best of our knowledge, this is the first reported case of EMH involving the uterine cervix which showed an association with tissue repair.